Format

Send to

Choose Destination
See comment in PubMed Commons below
J Perinatol. 2013 Mar;33(3):235-8. doi: 10.1038/jp.2012.70.

U-500R and aspart insulin for the treatment of severe insulin resistance in pregnancy associated with pregestational diabetes.

Author information

1
Department of Obstetrics, Gynecology and Reproductive Sciences, University of California at San Francisco and San Francisco General Hospital, San Francisco, CA 94110, USA.

Abstract

Severe insulin resistance as a complication of diabetes in pregnancy is seen with increasing frequency. Treatment with large doses of insulin (>300 units perday) can be practically difficult. A woman with preexisting Type 2 diabetes mellitus and poor glycemic control presented in early pregnancy requiring over 1000 units of insulin daily. She was transitioned to subcutaneous U-500 (concentrated regular insulin) in combination with a rapid-acting insulin analog achieving good glycemic control and good maternal and fetal outcomes. U-500R insulin in conjunction with a rapid-acting insulin analog can be used safely in early pregnancy to improve glycemic control in severe insulin resistance due to pregestational diabetes.

PMID:
23443293
DOI:
10.1038/jp.2012.70
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center